76902
document
The Eastern Cooperative Oncology Group experience with cyclophosphamide , adriamycin , and 5-fluorouracil ( CAF ) in patients with metastatic breast cancer . Data on 162 women ( 90 premenopausal and 72 postmenopausal ) with metastatic breast cancer randomized to receive cyclophosphamide , Adriamycin ( doxorubicin ) and 5-fluorouracil ( CAF ) on two Eastern Cooperative Oncology Group ( ECOG ) protocols were analyzed . Twenty-three percent had complete remission ; 39 % had partial remission ; 28 % had no change ; and 3 % had disease progression . Of those patients in whom receptors were known , response rates were 65 % for estrogen ( ER ) -receptor positive and 70 % for ER-negative patients . The median duration of response was 11.4 months . The median survival time from the start of CAF was 20.2 months . The response rate , time to treatment failure ( TTF ) , and median survival time were superior in the premenopausal women . These differences ceased , however , to be statistically significant in logistic models . Factors significantly associated with longer TTF and longer survival were as follows : one or two organs with metastases ( TTF , P less than 0.0001 ; survival , P less than 0.0001 ) ; dominant site other than soft tissue ( TTF , P less than 0.0001 ; survival , P = 0.05 ) ; and an initial good performance status ( TTF , P = 0.007 ; survival , P = 0.02 ) . Patients with ER-positive disease had a significantly longer median survival time ( P = 0.003 ) .
76903
Intervention_Pharmacological
cyclophosphamide , adriamycin , and 5-fluorouracil ( CAF )
76904
Intervention_Pharmacological
cyclophosphamide , Adriamycin ( doxorubicin ) and 5-fluorouracil ( CAF )
76905
Outcome_Other
median duration
76906
Outcome_Mortality
median survival time
76907
Outcome_Physical
response rate
76908
Outcome_Other
time to treatment failure ( TTF )
76909
Outcome_Mortality
median survival time
76910
Outcome_Other
TTF
76911
Outcome_Mortality
survival
76912
Outcome_Mortality
longer median survival time
76913
Participant_Condition
metastatic breast cancer
76914
Participant_Sample-size
162
76915
Participant_Sample-size
90
76916
Participant_Condition
premenopausal
76917
Participant_Sample-size
72
76918
Participant_Condition
postmenopausal
76919
Participant_Condition
metastatic breast cancer